加载中
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$3.90
−US$0.825 · -17.46%
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
前收盘价
US$3.90
−US$0.825 · -17.46%
盘前
US$4.03
+US$0.13 · +3.33%
10月13日 5:08 ET
盘中时间采用ET。市场数据可能有所延迟。
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
日内区间
当前US$3.90
52周区间
当前US$3.90
盘中时间采用ET。市场数据可能有所延迟。
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
日内区间
当前US$3.90
52周区间
当前US$3.90
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 616.2万 USD | 936.2万 USD | 253.2万 USD | 4803 USD | — |
| 销货成本 | 473.16万 USD | 598.3万 USD | 174.1万 USD | 467 USD | 4817 USD |
| 毛利 | 143.03万 USD | 337.9万 USD | 79.16万 USD | 4336 USD | −4817 USD |
| 研究与开发 | 208.91万 USD | 178.3万 USD | 172.5万 USD | 152.42万 USD | 113.8万 USD |
| 销售、一般及管理费用 | 991.37万 USD | 994.3万 USD | 679.1万 USD | 248.1万 USD | 106.89万 USD |
| 营业费用 | 1200.28万 USD | 1233.2万 USD | 876.5万 USD | 401.54万 USD | 220.2万 USD |
| 利息收入 | 2.34万 USD | 1.76万 USD | 12.21万 USD | 4.67万 USD | 424 USD |
| 利息支出 | 4.44万 USD | 9.25万 USD | 3.71万 USD | 253.3万 USD | 100.2万 USD |
| 折旧和摊销 | 50.48万 USD | 60.56万 USD | 24.96万 USD | 1.02万 USD | 4817 USD |
| 营业利润 | −1057.25万 USD | −895.3万 USD | −797.3万 USD | −401.11万 USD | −220.68万 USD |
| 净利润 | −1490.98万 USD | −904万 USD | −793.7万 USD | −815.41万 USD | −632.64万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
